

Informazione Regolamentata n. 0957-52-2025

Data/Ora Inizio Diffusione 5 Dicembre 2025 09:48:45

**Euronext Milan** 

Societa' : DIASORIN

Utenza - referente : DIASORINN01 - Ulisse Spada - Valerio

Vaccarone

Tipologia : 2.5

Data/Ora Ricezione : 5 Dicembre 2025 09:48:45

Data/Ora Inizio Diffusione : 5 Dicembre 2025 09:48:45

Oggetto : Communication on total amount of voting rights

## Testo del comunicato

See in attachment.





PRESS RELEASE •••

## COMMUNICATION ON TOTAL AMOUNT OF VOTING RIGHTS PURSUANT TO ARTICLE 85-BIS, PARAGRAPH 4-BIS, OF CONSOB REGULATION NO. 11971/1999

**Saluggia, December 5**th, **2025** – Diasorin S.p.A. ("Diasorin" or the "Company") hereby announces that some shareholders, holding equity interests lower than 3% of the overall voting rights – waived to the accrued increased voting rights, for overall no. 119,105 ordinary shares of the Company.

In accordance with Article 85-bis paragraph 4-bis, of Consob Regulation no. 11971/1999, the total amount of the voting rights is presented below, together with the number of shares making up the share capital:

	Status after assignment of increased voting rights			Status before assignment of increased voting rights		
	Number of shares making up share capital	No. of voting rights	Euro	Number of shares making up share capital	No. of voting rights	Euro
Total amount, of which:	55,948,257	88,041,075	55,948,257	55,948,257	88,160,180	55,948,257
Ordinary shares without increased voting rights ISIN IT0003492391	23,855,439	23,855,439	-	23,736,334	23,736,334	-
(regular dividend) Current coupon: no. 21						
Ordinary shares with increased voting rights	22,002,012	64105606		22 211 022	64 400 046	
IT0005188385 (regular dividend) Current coupon: no. 21	32,092,818	64,185,636		32,211,923	64,423,846	

The Special List, updated in accordance with Article 9-quater of the Company By-Laws, is available on the Company website https://int.diasorin.com/, in the Section "Company/Governance/Ownership Structure/Loyalty shares".





PRESS RELEASE •••

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

## FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava
Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.it

Eugenia Ragazzo

Corporate Investor Relations & ESG Analyst

eugenia.ragazzo@diasorin.it

Fine Comunicato n.0957-52-2025

Numero di Pagine: 4